Skip to main content
Home

Syndicate contentTourette's syndrome

Shire presents study findings on its ADHD treatments at psychiatric meeting Oct 29-30

HONOLULU -- October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Defi

Vyvanse CII significantly improved ADHD symptoms for children 13 hours after administration

PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi

VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD

Hollywood, FL -- July 1, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Nicotine antagonist relieves depression in children with Tourette's

A well-tolerated drug that blocks nicotine receptors in the brain appears to relieve depression and mood instability in children and adolescents with Tourette's syndrome, a preliminary study has found. The multicenter, placebo-controlled study of the drug mecamylamine is published in the latest issue of the journal Depression and Anxiety. "These preliminary findings are consistent with anecdotal observations that mecamylamine stabilizes mood," said lead author Douglas Shytle. "In addition, this is the first clinical evidence supporting the hypothesis that many antidepressants function, in part, by inhibiting nicotinic receptors."



About us

Science Blog was started in August 2002. It lives, breathes and eats press releases from research organizations around the globe. Most of what you read here are press releases from the outfits named in the stories themselves. Got a news story you think belongs here? Let's talk. The other half of the equation is blog posts from readers like you. So if you have an interest in science, please register and join others like you in an ongoing, vibrant dialog about what makes the world tick. Meantime, please take a minute to read our Privacy Policy and Site Disclaimer.




Premium Drupal Themes by Adaptivethemes